Session Chairs
Session Chair
Khadijah AlElaji, MD
Session Chair
Raul D. Santos, MD, MSc, PhD
1st Kuwait Familial Hypercholesterolemia Symposium & 4th Severe FH Masterclass - Day 1
Pre-activity information
The 1st Kuwait Familial Hypercholesterolemia Symposium and the 4th IAS Severe FH Master Class is targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease.
Upon completion of this program participants should be able to:
1) Recognize, diagnose, and treat severe familial hypercholesterolemia (both HeFH and HoFH) in accordance with current guidelines.
2) Discuss the implications of family history, consanguinity, and cascade screening.
3) Discuss the complications of familial hypercholesterolemia.
4) Discuss HoFH and pregnancy.
5) Discuss HoFH and COVID-19.
6) Outline the clinical indications of LDL apheresis.
7) Evaluate the efficacy, safety, and tolerability of various drugs for the treatment of severe familial hypercholesterolemia to implement appropriately targeted treatment plans.
8) Diagnosis and management of pediatric HeFH and HoFH.
9) Work collaboratievely to analyze and discuss several case studies.
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found by clicking on their name.
Raul D. Santos, MD, MSc, PhD
| Disclosures | Date of Disclosures |
| Honorarium for research activities from Amgen, Kowa, Esperion, Sanofi/Regeneron. Honorarium for speaker activities from Amgen, Ache, Astra Zeneca, Merck, MSD, Pfizer, PTC and Novo Nordisk. | 19-02-2021 |
Khalid Al Rasadi, MD
| Disclosures | Date of Disclosures |
| Consultant or advisory board member from Astra Zeneca, Pfizer, Sanofi, Aegerion and Abbott. Grant and Research support received from Sanofi. | 19-02-2021 |
Dirk Blom, MBChB, MMed, FCP (SA) PhD
| Disclosures | Date of Disclosures |
|
Honoraria for advisory boards: Sanofi, Amgen. Speaker fees: Sanofi, Amgen, Amryt, Novartis, Abbott. Clinical trials – payment to institution: Amgen, Sanofi, Regeneron, Novartis |
19-02-2021 |
Robert Hegele MD, FRCPC
| Disclosures | Date of Disclosures |
|
Grants/Research Support: CIHR, HSFO, Acasti, Akcea/Ionis, Amgen, Sanofi. Speakers Bureau/Honoraria: Ackea, Amgen, Sanofi. Consulting Fees: Acasti Aegerion, Akcea/Ionis, Amgen, Genzyme, Sanofi, Regeneron. Trial Participation: Acasti, Sanofi, Amgen, The Medicines Co., Aegerion, Regeneron, Akcea, Cerenis |
19-02-2021 |
Frederick Raal, MBBCh, FRCP, FCP(SA), Cert Endo, MMED, PhD
| Disclosures | Date of Disclosures |
| Professor Raal has received research grants, honoraria, or consulting fees for professional input and/or delivered lectures from Sanofi, Regeneron, Amgen and Novartis. | 19-02-2021 |
Thamer Alessa, MD, FACE, CCD
| Disclosure | Date of Disclosures |
| Thamer Alessa has received Advisory Board fees from Sanofi-Aventis, MSD, and Amgen, Honoraria from Sanofi-Aventis, MSD, and Amgen. | 19-02-2021 |
Khadijah AlElaj, MD
There are no Disclosure Statements for Dr. Al-Elaj
Alberico Catapano, MD
There are no Disclosure Statements Dr. Alberico Catapano
Mousa Akbar, MD
There are no Disclosure Statements Dr. Mousa Akbar
Staff Disclosures
Staff involved with the development of this activity have nothing to disclose.
The IAS is very grateful to Amryt Pharma, Amgen, Kaneka, Sanofi and AAW for supporting the 1st Kuwait Familial Hypercholesterolemia Symposium & 4th Severe FH Masterclass through an unrestricted educational grant. We also thank all the faculty and clinician attendees who shared their experience and contributed to the IAS in its global mission.
Activity
NAFLD/NASH and ASCVD Connection: Final Messages
Combined Patient Management
Patient Identification and Risk Stratification
ASCVD and NAFLD/NASH: the Background of the Connection
Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?
Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?
Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares
Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA
Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2
Parte 1 – A história na batalha da insulina e glucagon
Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease
Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD
Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient
Part 1: The History in the Battle of Insulin and Glucagon
Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil)
Discusión Foro 4 – Panelist Roopa Mehta (Mexico)
Nuevas terapias para la HF grave – Paola Varleta (Chile)
Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica)